Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12622000680763
Ethics application status
Approved
Date submitted
31/03/2022
Date registered
11/05/2022
Date last updated
15/10/2023
Date data sharing statement initially provided
11/05/2022
Date results information initially provided
23/05/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period
Query!
Scientific title
To evaluate the safety, tolerability and efficacy in male and female with androgenetic alopecia treated with HMI-115 over a 24-week treatment period
Query!
Secondary ID [1]
306793
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Androgenetic Alopecia
325861
0
Query!
Condition category
Condition code
Skin
323173
323173
0
0
Query!
Dermatological conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
All eligible subjects will receive HMI-115 240 mg once every two weeks, subcutaneous injection during onsite visit by pharmacist, during the treatment period of 24 weeks.
Query!
Intervention code [1]
323256
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
330925
0
Change in target area hair count (TAHC) of non-vellus from baseline to Week 24 in male and female Androgenetic Alopecia (AGA) subjects through photo review, respectively.
Query!
Assessment method [1]
330925
0
Query!
Timepoint [1]
330925
0
Baseline, 24 weeks post-intervention commencement
Query!
Secondary outcome [1]
408106
0
Change in TAHC of non-vellus from baseline to Week 6, 12, 18, and 36 in male and female through photo review, respectively.
Query!
Assessment method [1]
408106
0
Query!
Timepoint [1]
408106
0
Baseline, and weeks 6, 12, 18, and 36 post-intervention commencement
Query!
Secondary outcome [2]
408235
0
Change in target area hair width (TAHW) of non-vellus hair from baseline to Week 6, 12, 18, 24, and 36 in male and female through photo review, respectively.
Query!
Assessment method [2]
408235
0
Query!
Timepoint [2]
408235
0
Baseline, and weeks 6, 12, 18, 24, and 36 post-intervention commencement.
Query!
Secondary outcome [3]
408236
0
Investigator Global Assessment (IGA) will be assessed by investigator, to evaluate the change in hair growth over time as compared to Baseline, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased).
Query!
Assessment method [3]
408236
0
Query!
Timepoint [3]
408236
0
Weeks 6, 12, 18, 24, and 36 post-intervention commencement.
Query!
Secondary outcome [4]
408464
0
Subject Self-Assessment (SSA) IGA will be assessed by subject, to evaluate the change in hair growth over time as compared to Baseline, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased).
Query!
Assessment method [4]
408464
0
Query!
Timepoint [4]
408464
0
Weeks 6, 12, 18, 24, and 36 post-intervention commencement.
Query!
Secondary outcome [5]
408465
0
Hair Groutth questionnaire assessment (HGQA) is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study, using a study specific questionnaire.
Query!
Assessment method [5]
408465
0
Query!
Timepoint [5]
408465
0
Weeks 6, 12, 18, 24, and 36 post-intervention commencement.
Query!
Secondary outcome [6]
408466
0
safety and tolerability of HMI-115 as assessed by vital signs, physical examinations, concomitant medication, electrocardiogram, clinical laboratory test and review of adverse events.
Vital signs include blood pressure assessed by sphygmomanmeter, tympanic body temperature assessed by thermometer, pulse, and respiratory rate
Concomitant medication will be collected by participant self-report during the visit.
Clinical laboratory tests include Hematology, Coagulation, Clinical Chemistry, Additional Chemistry, Sex hormone, Viral serology, Pharmacokinetics (PK) and Anti-drug Antibody (ADA) of serum , Urinalysis of urine, pregnancy test of serum and urine.
The intensity of AEs will be assessed by investigator using the categories as mild, moderate and severe.
Query!
Assessment method [6]
408466
0
Query!
Timepoint [6]
408466
0
the frequency of Vital signs, concomitant medication, and adverse events: every 2 weeks from baseline to 36 weeks post-intervention commencement
the frequency of clinical laboratory tests: 4, 12, 20, 24, and 36 weeks post-intervention commencement
Query!
Eligibility
Key inclusion criteria
1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
2. Male and Female subjects, between 18 and 65 years of , inclusive, at the time of signing informed consent.
3. Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales 3v, 4 and 5. Female subjects who meet Sinclair scales 2-4.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Subject with clinical diagnosis of non-AGA (Androgenetic Alopecia_
2. Subject with clinically relevant abnormal skin or scalp findings which could interfere study assessment
3. Subject has used therapies associated with hair growth or therapy with confirmed effects on PRL level, within defined time window before screening.
4. Subject with history of another pituitary, posterior pituitary, or hyperthyroidism
5. Subject has clinically significantly abnormal laboratory tests at Screening
6. Known hypersensitivity to any of the IMP (Investigational Medicinal Product) ingredients
7. Any other conditions in the investigator's opinion that prevent the subject from participating
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
15/05/2022
Query!
Actual
22/07/2022
Query!
Date of last participant enrolment
Anticipated
4/10/2022
Query!
Actual
17/11/2022
Query!
Date of last data collection
Anticipated
6/09/2023
Query!
Actual
11/09/2023
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
16
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
311099
0
Commercial sector/Industry
Query!
Name [1]
311099
0
Hope Medicine (Nanjing) Co., Ltd
Query!
Address [1]
311099
0
Building 16-B2-1 of Tree House Headquarter, No.73 Tanmi Road, Jiangbei New Area, Nanjing City 201203
Query!
Country [1]
311099
0
China
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hope Medicine (Nanjing) Co., Ltd
Query!
Address
Building 16-B2-1 of Tree House Headquarter, No.73 Tanmi Road, Jiangbei New Area, Nanjing City 400025
Query!
Country
China
Query!
Secondary sponsor category [1]
312427
0
Commercial sector/Industry
Query!
Name [1]
312427
0
Clinipace Australia Pty Ltd
Query!
Address [1]
312427
0
Suite 12 Level 12 / 37 Bligh Street Sydney NSW 2000
Query!
Country [1]
312427
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
310632
0
Bellberry Limited
Query!
Ethics committee address [1]
310632
0
123 Glen Osmond Road, Eastwood SA 5063
Query!
Ethics committee country [1]
310632
0
Australia
Query!
Date submitted for ethics approval [1]
310632
0
22/12/2021
Query!
Approval date [1]
310632
0
09/03/2022
Query!
Ethics approval number [1]
310632
0
2021-11-1331
Query!
Summary
Brief summary
HMI-115 re-established the growth phase for hair follicles to stimulate hair regrowth through blocking the function of prolactin on hair follicles. it is expected that HMI-115 will resolve current clinical unmet needs, not only provide excellent and durable efficacy of hair growth for man and women, but also provide a favorable safety profile. This study aims to explore the preliminary efficacy and safety of HMI-115 in male and female AGA patients aged 18 to 65 years (inclusive) at 240 mg every 2 weeks (Q2W).
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
118330
0
Dr Rodney Daniel Sinclair
Query!
Address
118330
0
Dr Rodney Sinclair Pty Ltd, trading as Sinclair Dermatology
Level 3, 2 Wellington Parade,
East Melbourne VIC 3002
Query!
Country
118330
0
Australia
Query!
Phone
118330
0
+61396542426
Query!
Fax
118330
0
Query!
Email
118330
0
[email protected]
Query!
Contact person for public queries
Name
118331
0
Ms HopeMed Clinical Trial Posting Group
Query!
Address
118331
0
Hope Medicine (Nanjing) Co.,Ltd.
Room 306, Building Y1, No. 112 Liangxiu Road, Pudong New Area, Shanghai China 201203
Query!
Country
118331
0
China
Query!
Phone
118331
0
+86 21 50760962
Query!
Fax
118331
0
Query!
Email
118331
0
[email protected]
Query!
Contact person for scientific queries
Name
118332
0
Ms HopeMed Clinical Trial Posting Group
Query!
Address
118332
0
Hope Medicine (Nanjing) Co.,Ltd.
Room 306, Building Y1, No. 112 Liangxiu Road, Pudong New Area, Shanghai China 201203
Query!
Country
118332
0
China
Query!
Phone
118332
0
+86 21 50760962
Query!
Fax
118332
0
Query!
Email
118332
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF